| 000 | 01819 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515035530.0 | ||
| 264 | 0 | _c20060914 | |
| 008 | 200609s 0 0 eng d | ||
| 022 | _a0003-9926 | ||
| 024 | 7 |
_a10.1001/archinte.166.15.1561 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNides, Mitchell | |
| 245 | 0 | 0 |
_aSmoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. _h[electronic resource] |
| 260 |
_bArchives of internal medicine _c |
||
| 300 |
_a1561-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBenzazepines _xadverse effects |
| 650 | 0 | 4 |
_aBupropion _xtherapeutic use |
| 650 | 0 | 4 |
_aDopamine Uptake Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHealth Status |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNicotinic Agonists _xadverse effects |
| 650 | 0 | 4 |
_aNicotinic Antagonists _xadverse effects |
| 650 | 0 | 4 |
_aQuinoxalines _xadverse effects |
| 650 | 0 | 4 |
_aSmoking Cessation _xmethods |
| 650 | 0 | 4 |
_aTobacco Use Disorder _xdrug therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aVarenicline |
| 700 | 1 | _aOncken, Cheryl | |
| 700 | 1 | _aGonzales, David | |
| 700 | 1 | _aRennard, Stephen | |
| 700 | 1 | _aWatsky, Eric J | |
| 700 | 1 | _aAnziano, Rich | |
| 700 | 1 | _aReeves, Karen R | |
| 773 | 0 |
_tArchives of internal medicine _gvol. 166 _gno. 15 _gp. 1561-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/archinte.166.15.1561 _zAvailable from publisher's website |
| 999 |
_c16496080 _d16496080 |
||